1	The plasma metabolome of long COVID-19 patients two years after infection
2	Yamilé López-Hernández ¹ , Joel Monárrez Aquino ² , David Alejandro García López ³ ,
3	Jiamin Zheng ⁴ , Juan Carlos Borrego ⁵ , Claudia Torres-Calzada ⁴ , José Pedro Elizalde-Díaz ⁶ ,
4	Rupasri Mandal ⁴ , Mark Berjanskii ⁴ , Eduardo Martínez-Martínez ⁶ , Jesús Adrián López ⁷ ,
5	David S. Wishart ⁴ *
6	
7	¹ CONACyT- Metabolomics and Proteomics Laboratory, Academic Unit of Biological
8	Sciences, Autonomous University of Zacatecas, Zacatecas, 98000, Mexico.
9	² Department of Health Research. Christus Muguerza del Parque Hospital – University of
10	Monterrey. Chihuahua, 31125, México.
11	³ Academic Unit of Biological Sciences, Autonomous University of Zacatecas, Zacatecas,
12	98000, Mexico.
13	⁴ The Metabolomics Innovation Centre, University of Alberta, Edmonton, AB T6G 1C9,
14	Canada.
15	⁵ Departamento de Epidemiología, Hospital General de Zona #1 "Emilio Varela Luján",
16	Instituto Mexicano del Seguro Social, Zacatecas, 98000, México.
17	⁶ Laboratory of Cell Communication & Extracellular Vesicles, Division of Basic Science,
18	Instituto Nacional de Medicina Genómica, Ciudad de México, 14610, Mexico.
19	⁷ MicroRNAs and Cancer Laboratory, Academic Unit of Biological Sciences, Autonomous
20	University of Zacatecas, Zacatecas, 98000, Mexico.
21	
22	*Corresponding author: dwishart@ualberta.ca
23	

24 ABSTRACT

25 Background: One of the major challenges currently faced by global health systems is the 26 prolonged COVID-19 syndrome (also known as "long COVID") which has emerged as a consequence of the SARS-CoV-2 epidemic. The World Health Organization (WHO) 27 28 recognized long COVID as a distinct clinical entity in 2021. It is estimated that at least 30% 29 of patients who have had COVID-19 will develop long COVID. This has put a tremendous 30 strain on still-overstretched healthcare systems around the world. Methods: In this study, 31 our goal was to assess the plasma metabolome in a total of 108 samples collected from 32 healthy controls, COVID-19 patients, and long COVID patients recruited in Mexico 33 between 2020 and 2022. A targeted metabolomics approach using a combination of LC-34 MS/MS and FIA MS/MS was performed to quantify 108 metabolites. IL-17 and leptin 35 concentrations were measured in long COVID patients by immunoenzymatic assay. 36 Results: The comparison of paired COVID-19/post-COVID-19 samples revealed 53 37 metabolites that were statistically different (FDR < 0.05). Compared to controls, 29 38 metabolites remained dysregulated even after two years. Notably, glucose, kynurenine, and 39 certain acylcarnitines continued to exhibit altered concentrations similar to the COVID-19 40 phase, while sphingomyelins and long saturated and monounsaturated LysoPCs, 41 phenylalanine, butyric acid, and propionic acid levels normalized. Post-COVID-19 patients 42 displayed a heterogeneous metabolic profile, with some showing no symptoms while others exhibiting a variable number of symptoms. Lactic acid, lactate/pyruvate ratio, 43 44 ornithine/citrulline ratio, sarcosine, and arginine were identified as the most relevant 45 metabolites for distinguishing patients with more complicated long COVID evolution. 46 Additionally, IL-17 levels were significantly increased in these patients. Conclusions: 47 Mitochondrial dysfunction, redox state imbalance, impaired energy metabolism, and

- 48 chronic immune dysregulation are likely to be the main hallmarks of long COVID even two
- 49 years after acute COVID-19 infection.
- 50 Keywords: long COVID, PACS, targeted metabolomics, mass spectrometry, COVID-19

51 Background

52 Historically, highly pathogenic beta-coronaviruses have been associated with severe 53 respiratory diseases. According to the WHO, the severe acute respiratory syndrome 54 coronavirus (SARS-CoV), and the Middle East respiratory syndrome coronavirus (MERS-55 CoV) were responsible for epidemics in 2002-2003 and 2015, respectively. During the 56 SARS-CoV epidemic, the virus was reported in 29 countries with 8,437 cases and 813 57 fatalities [1]. On the other hand, MERS-CoV was reported in 27 countries with 2,519 58 laboratory-confirmed cases between 2012 and 2020, resulting in 866 deaths [2]. In 2019, 59 exactly 100 years after the last pandemic caused by an H1N1 influenza A virus (the 60 Spanish flu), a new pandemic affected almost every country around the world. As of 61 February 26, 2023, over 758 million confirmed cases of SARS-CoV-2 and over 6.8 million 62 deaths have been reported globally. To date, around 653 million patients have recovered 63 [3]. However, as early as spring 2020, people began describing their experiences of not 64 fully recovering from SARS-CoV-2 infection [4]. This extended version of the disease has 65 been called "long COVID". Interestingly, the term long COVID is a patient-created term 66 promoted in Twitter by Elsa Perego, an archeologist at University College London.

67 It has been widely described that some viruses lead to persistent physiological 68 alterations even a decade after infection. The term "post-viral syndrome" has been in use 69 for over a century [5]. Chronic symptoms such as fatigue, joint pain, and cardiovascular 70 problems have been reported after recovery from other infections such as the West Nile, 71 Polio, Dengue, Zika, seasonal flu, Epstein-Barr, Ebola, MERS, and SARS [6, 7]. However, 72 none of these viruses have affected so many people in the same time window as SARS-73 CoV-2, which offers the scientific community a unique opportunity to understand the 74 etiology of post-viral syndromes such as long COVID.

75 Long COVID (also known as post-COVID-19 syndrome or post-acute sequelae of 76 COVID-19 (PACS)) is a condition characterized by long-term or persistent health problems 77 appearing after the initial recovery from COVID-19 infection. The WHO has described 78 long COVID as a condition "that occurs in individuals with a previous history of probable 79 or confirmed SARS-CoV-2 infection, usually three months after the onset, with symptoms 80 lasting at least two months that cannot be explained by an alternative diagnosis" [8]. It is 81 estimated that 30-60% of recovered patients, even after a mild disease, will experience long 82 COVID or symptoms persistence with varying durations [9]. Based on a conservative 83 estimated incidence, at least 65 million individuals worldwide could be experiencing long 84 COVID [3].

85 Similar to COVID-19, long COVID affects multiple organ systems, including the 86 respiratory, cardiovascular, nervous, and gastrointestinal systems. More than 50 symptoms 87 have been reported associated with long COVID [10]. Observational studies have reported 88 that some symptomatic conditions are resolved within three months of hospitalization in 89 50% of patients [11], but the rate of full recovery drops to 35% between three and six 90 months after hospitalization, and to 15% between six to nine months. Importantly, a high 91 proportion of that population has residual lung tissue injury, with detectable radiological 92 abnormalities on chest computed tomography (CT) scans [12]. Fatigue, loss of 93 concentration, headaches, shortness of breath, anosmia, muscle weakness, joint pain are 94 some of the symptoms most reported. Therefore, more than a homogeneous entity, long 95 COVID could be considered as a spectrum of disorders, that affects individuals with 96 complications directly linked to the virus (long-term residual damage in the lungs, brain, or heart), and individuals manifesting systemic unspecific signs/symptoms (fatigue, headache, 97 98 and arthromyalgias) [13]. The increasing number of patients with long COVID poses a

99 challenge for public health systems around the world, but, currently, there are no guidelines
100 for accurately diagnosing patients with long COVID and classification is still
101 underestimated and subjective.

102 In the present work we used quantitative targeted metabolomics to evaluate the 103 metabolic reversion of patients with persistent sequelae due to confirmed SARS-CoV-2 104 infection. Comparison with negative controls allowed us to identify those metabolites 105 persistently dysregulated after two years of the initial infection. Number, type of symptoms 106 as well as metabolic signatures were different in patients experiencing long COVID. 107 Besides, IL-17 level was increased in patients with the worst disease evolution. To the best 108 of our knowledge, this is the first targeted metabolomics study of long COVID patients 109 conducted beyond twenty months post-infection.

110

111 Methods

112 **Patient recruitment**

113 For the aims of this study, COVID-19 patient survivors (with confirmed diagnostic based 114 on a positive PCR for SARS-CoV-2) who developed a mild, severe, or critical disease, and were admitted (or hospitalized) in the Instituto Mexicano de Seguridad Social (Zacatecas 115 116 city, Mexico) and Christus Muguerza del Parque Hospital (Chihuahua city, Mexico) 117 between March and November 2020, were recruited. Participants were contacted for a 118 face-to face interview. They were invited to respond to a questionnaire and to donate a 119 blood sample. Plasma was isolated from the donated blood. COVID-19 patients from the 120 Instituto Mexicano de Seguridad Social were recruited from an initial set of 124 COVID-19 121 patients enrolled in a previous research study [14]. Of these, 44 (35.6%) passed away 122 during hospitalization and in the following months after hospital discharge. From 80

123 survivors, it was possible to contact 36 (by their Social Security Number or 124 personal/relative phone number kept in hospital records), and 15 agreed to participate. For 125 these 15 patients, paired plasma samples from the first diagnosis of the acute disease 126 (COVID-19 group) and post-COVID phase were available.

Additionally, from a cohort of patients that were hospitalized in 2020 in Christus Muguerza del Parque Hospital, 33 were randomly selected by age stratification. For those patients, a basal blood sample was not available; however, all clinical information and chest computed tomography (CT) scans were recorded in the hospital archive.

For the neuropsychological assessment, the validated Hamilton Anxiety Rating Scale (HAM-A) [15] was used. For depression assessment, the Hamilton Depression scale (HAM-D) was used [16]. The Montreal Cognitive Assessment (MoCA) was employed for cognitive impairment [17]. For dyspnea assessment, the modified Medical Research Council (mMRC) dyspnea scale was implemented [18]. Basic blood biochemical markers were performed (i.e., hemoglobin, platelets, leukocytes, lymphocytes, and creatinine) for all enrolled patients.

138 To assess for differences in the severity of long COVID patients, our own 139 classification was made (arbitrarily) considering the frequency of concomitant symptoms. 140 Recovered patients were classified as those who did not report persistent symptoms. Long 141 COVID was considered if patients reported at least one persistent neurologic, psychiatric, 142 gastrointestinal, cardiologic, respiratory, or systemic symptom. The Class A long COVID 143 patients were those reporting less than five persistent symptoms (17 patients), while class B 144 long COVID patients were those reporting five or more persistent symptoms (13 patients). 145 As negative controls and an indicator of normal population, stored plasma samples from 37 146 individuals who tested negative for SARS-CoV-2 in 2020 were used.

This study was conducted in accordance with the Declaration of Helsinki (1976). It was also revised and approved by the Research and Ethics Committees of the Instituto Mexicano de Seguridad Social, with the registration number R-2022-3301-038, and Christus Muguerza del Parque Hospital (HCMP-CEI-15042020-3, and HCMP-CEI-28022022-A01). Informed consent was obtained from all participants. All patients included in this study were informed in writing regarding the collection of their samples for research aims and were given the right to refuse participation.

154 Metabolomics analysis

A combination of direct injection mass spectrometry with a reverse-phase LC-MS/MS custom assay was used, as previously described [14]. Briefly, metabolites were measured using a locally developed LC–MS/MS metabolomics assay called The Metabolomics Innovation Centre (TMIC) Prime (TMIC PRIME®) Assay. This assay provides quantitative results for up to 143 endogenous metabolites, including biogenic amines, amino acids, organic acids, lipids, and lipid-like compounds.

161 The method combines the derivatization and extraction of analytes, and the selective 162 mass-spectrometric detection using multiple reaction monitoring (MRM) pairs. Isotope-163 labeled internal standards and other internal standards were used for metabolite 164 quantification. The custom assay uses a 96 deep-well plate with a filter plate attached via 165 sealing tape, and reagents and solvents used to prepare the plate assay. The first 14 wells of 166 the 96-well plate were used for calibration and quality control with one double blank, three 167 zero samples, seven calibration standards and three quality control samples. To measure all 168 metabolites except organic acids, samples were first thawed on ice and were vortexed. 10 169 µL of each sample was loaded onto the center of the filter on the upper 96-well plate and 170 dried under a stream of nitrogen. Subsequently, phenyl-isothiocyanate (PITC) was added

171 for derivatization. After incubation, the filter spots were dried again using an evaporator. 172 Extraction of the metabolites was then achieved by adding 300 μ L of extraction solvent. 173 The extracts were obtained by centrifugation into the lower 96-deep well plate, followed by 174 a dilution step with the mass spectrometry running solvent.

For organic acid analysis, $150 \ \mu$ L of ice-cold methanol and $10 \ \mu$ L of isotope-labeled internal standard mixture was added to $50 \ \mu$ L of each plasma sample for overnight protein precipitation. Each sample was then centrifuged at 13000 x g for 15 min. 50 μ L of supernatant was loaded into the center of wells of a 96-deep well plate, followed by the addition of ¹³C labeled 3-nitrophenylhydrazine (3-NPH) as an isotopic labeling reagent (for quantification). After incubation for 2h, butylated hydroxytoluene (as a stabilizer) and water were added before LC-MS injection.

Mass spectrometric analysis for the PITC-derivatized and 3-NPH-derivatized samples was performed on an ABSciex 4000 Qtrap® tandem mass spectrometry instrument (Applied Biosystems/MDS Analytical Technologies, Foster City, CA) equipped with an Agilent 1260 series UHPLC system. Organic acids, biogenic amines, amino acids, and amino acid derivatives were detected and quantified via LC-MS, while lipids, acylcarnitines, and glucose were detected and quantified via a direct injection (DI) method.

Analyst 1.6.2 and MultiQuant 3.0.3 was used for quantitative analysis. An individual seven-point calibration curve was generated to quantify organic acids, amino acids, biogenic amines, and derivatives. Ratios for each analyte's signal intensity to its corresponding isotope-labelled internal standard were plotted against the specific known concentrations using quadratic regression with a $1/x^2$ weighting. For lipids, acylcarnitines, and glucose, a single point calibration of a representative analyte was built using the same

194 group of compounds that share the same core structure assuming a linear regression 195 through zero.

196 **Plasma IL-17 and leptin determinations**

197 ELISA kits were used for the quantification of IL-17 (Catalog Number RAB0262, Sigma-198 Aldrich, St. Louis, MO, USA) and leptin (catalog number ab108879, Abcam, Cambridge, 199 UK), following manufacturer's instructions. Briefly, standard solutions (or plasma 200 samples), were added to each type of pre-coated 96-well plate and incubated overnight at 201 4°C. The plates were then incubated with the corresponding detection antibodies (100 202 μ L/well) for 1 h at room temperature. Streptavidin solution (100 μ L) was then added to 203 each well and the plates were incubated for 45 min. After the antibody-HPR incubation, 204 TMB one-step substrate reagent (100 µL) was added to the wells and the plates were 205 incubated for another 30 min before the addition of a stop solution (50 µL/well). 206 Absorbance values (at 450 nm) were used for the calculation of the protein concentrations 207 (pg/mL) by comparing the absorbance to an appropriate standard curve.

208 Statistical analysis

209 To describe baseline characteristics of negative controls (non-COVID-19), COVID-19 or 210 post-COVID-19 patients, medians with interquartile ranges (IQRs) or means [with standard 211 deviations (s.d.)] and frequencies (%) were used for continuous and categorical data, 212 respectively. Normality was assessed using the D'Agostino-Pearson normality test. 213 Student's t-test or Mann-Whitney tests were used for continuous data. For categorical variables (e.g., sex, smoking, symptoms, and comorbidities) Pearson Chi² tests or Fisher's 214 215 exact tests were used. All p-values less than 0.05 (p<0.05) were considered statistically 216 significant. Analyses were conducted using SPSS (IBM, version 24).

217 Metabolite analysis was performed with MetaboAnalyst 5.0 [19]. Those metabolites 218 with more than $\Box 20\%$ of missing values were removed from further analysis. For the 219 remaining metabolites, values below the limit of detection (LOD) were imputed using 1/5 220 of the minimum positive value of each variable. The data were then subject to median 221 normalization, log-transformed and Pareto-scaled to generate appropriate Gaussian 222 metabolite concentration distributions. Differences in mean metabolic values between 223 controls, COVID-19, post-COVID-19, and long COVID patients were assessed using a 224 parametric t-test or one-way ANOVA [adjusted p-value (FDR) cut-off = 0.05]. For the 225 paired study, t-test, and volcano plots of log-transformed p-values were generated to 226 address significant metabolites. Principal component analysis (PCA) and two-dimensional 227 partial least squares discriminant analysis (2-D PLS-DA) scores plots were used to compare 228 plasma metabolite data across and between study groups; 2000-fold permutation tests were 229 used to assess statistical significance and minimize the possibility that the observed 230 separation of the PLS-DA clusters was due to chance. Differentiated metabolites were 231 identified by a variable importance in projection (VIP) using a score cutoff of >1.5. Heat 232 maps of the top 50 significant metabolites (via t-test or ANOVA) were created via 233 MetaboAnalyst.

Pathway analysis was done using Metabolite Set Enrichment Analysis (MSEA) and Metabolomic Pathway Analysis (MetPA) modules as found in MetaboAnalyst 5.0 [19]. The Homo sapiens pathway library was used for pathway analysis. The global test was used for the selected pathway enrichment analysis method, whereas the node importance measure for topological analysis was used to assess the relative betweenness centrality.

The metabolites with the highest VIP scores and LASSO frequencies were used to create metabolite panels for predicting long COVID using multivariate logistic regression.

Additionally, models were adjusted for relevant potential confounders such as sex, age, relevant comorbidities (i.e., DM-II, HTN, and obesity), so that only statistically significant variables (p = < 0.05) remained in the final models. Logistic regression analysis was performed with the Pareto-scaled data. K-fold cross-validation (CV) was used to ensure that the logistic regression models were robust. To determine the performance of each generated model, the area under the receiver operating characteristics curve (AUROC or AUC) was calculated, as was sensitivity and specificity.

- 248
- 249 **Results**

250 **Demographic, clinical data and symptoms description**

251 **Table 1** shows baseline characteristics of patients enrolled in the study. Age was 252 statistically different between negative (healthy) controls and COVID-19 patients. 253 However, differences were not found in the self-reported comorbidities. Six patients 254 (12.5%) developed mild disease; 37 patients developed (77%) moderate/severe disease 255 while five patients (10.4%) developed critical disease. Six patients (12.5%) were reinfected 256 during 2021 and 2022. All patients were fully vaccinated during the period of 2021-2022. 257 The questionnaire answered by the patients revealed the most persistent symptoms which 258 were grouped into five broad categories: systemic, neurologic, psychiatric, cardiologic, and 259 respiratory. The most predominant symptoms were loss of memory (73.3%), sleep 260 disorders, arthralgia, fatigue, exercise intolerance, myalgia (66.7%), and anxiety (60.0%).

261 **Table 1:** Baseline characteristics of participants in the study

Variable	Controls	COVID-19	post-COVID-19	long COVID	p-value
	(N=38)	(N=15)	(N=48)	(N=29)	
Age, median (Q1-	40.5 (37-	51 (44.3-59.3)	51.5 (43.5-60.8)	50.5 (44.3-62)	0.0079 * ^{a, b, c}

Q3)	53.3)				
Male gender, n (%)	17 (44.7)	12 (54.5)	28 (58.3)	9 (34.6)	0.2226
Smoking, n (%)	4 (10.5)	3 (13.6)	7 (14.6)	3 (11.5)	0.7231
Comorbidities (self-re	eported), n (%)			
Diabetes	3 (7.9)	3 (13.6)	7 (14.6)	3 (11.5)	0.7833
Hypertension	9 (23.7)	6 (27.3)	20 (41.7)	9 (34.6)	0.1035
Obesity	3 (7.9)	0 (0)	5 (10.4)	2 (7.7)	0.3823
Laboratory data, mee	dian (Q1-Q3)				
Hemoglobin (g/dL)	15.3 (14.4-	14.4 (12.6-16.2)	15.4 (14.5-16.1)	15.5 (14.68-	0.7833
	16.2)			16.23)	
Platelets	276 (236.5-	177 (68.2-	242.5 (219.8-290.5)	242.3 +/- 69.7	0.1035
(thousands/ mL)	325.5)	281.8)			
Leukocytes ($\times 10^3$)	7.1 (6.0-8.3)	6.7 (4.4-11.1)	7.0 (6.2-7.8)	7.3 (6.5-7.7)	0.3823
Lymphocyte counts	31.8 (25.5-	12.1 (4.9-22.1)	33.8 (29-38.9)	34 +/-7.1	<0.0001 * ^{a, d, e}
(%)	36.4)				
Creatinine (mg/dL)	0.9 (0.7-1.1)	0.7 (0.6-0.9)	0.8 (0.7-1.0)	0.8 (0.7-0.9)	0.2452
a: negative control	s vs. COVIE	0-19; b: COVID	-19 vs. post-COVID-	19; c: negative cor	ntrols
vs. post-COVID-19	9: d: COVII)-19 vs. Post-C(OVID-19: e: COVID-	-19 vs. long COVI	D: f:
	-,				
Post-COVID-19		VS.	long	CC	0VID
Paired analysis: C	COVID-19/p	ost-COVID-19	phases		
When naired sam	nles (COV)	$[D_{-}19/p_{0}t_{-}COV]$	$VID_{-}19$) from 15 ps	tients were com	pared

268 metabolically, 53 plasma metabolites were found to be significantly different (FDR < 0.05). 269 **Supplementary Table 1** shows the results of the t-test (autoscaling normalization). The 270 volcano plot (**Figure 1A**) shows that 13 metabolites were significantly upregulated in the 271 post-COVID-19 phase, while 32 were downregulated with a fold change (FC) threshold >

262

263

264

265

266

272 1.3 (FDR <0.05). Heatmap analysis (Figure 1B) shows a clustering of patients 273 corresponding to their COVID-19 and post-COVID phases, revealing that lysoPCs (except LysoPC 18:2) and SMs were downregulated in the post-COVID phase. Multivariate 274 275 analysis (via PLS-DA) demonstrated a clear separation between both COVID phases (accuracy: 0.97, R²: 0.94, O²: 0.77) (Figure 1C). The VIP plot (Figure 1D) shows that 276 277 phenylalanine, taurine, and spermidine had lower plasma concentrations in the post-278 COVID-19 phase, while the glutamine/glutamate ratio was increased in the post-COVID-279 19 phase.

280 **Post-COVID-19 patients compared with controls**

281 In order to know if the altered metabolites (and those that remained unsignificant) were 282 dysregulated with respect to normal values, a group of negative SARS-CoV-2 controls (i.e., 283 healthy controls) collected from 2020 was added to the analysis. The heatmap (Figure 2A) 284 shows the metabolites with significant differences across the three study groups (one way 285 ANOVA). Volcano plots (Figure 2B) were used to identify the dysregulated metabolites in 286 the post-COVID-19 patients with respect to the healthy controls. Two-sample t-tests & 287 Wilcoxon rank-sum tests shows that in comparison with the healthy controls, 29 metabolites were still dysregulated in post-COVID patients (Supplementary Table 2). 288 C18:1(adjusted $p = 4 \ge 10^{-3}$), C18:2 (adjusted $p = 6.1 \ge 10^{-6}$), C10:2 (adjusted $p = 7 \ge 10^{-3}$), 289 C10:1(adjusted $p = 3 \times 10^{-2}$), carnitine (adjusted $p = 4 \times 10^{-2}$) as well as glutamine (adjusted 290 $p = 4.2 \times 10^{-5}$), choline (adjusted $p = 5.7 \times 10^{-5}$), glucose (adjusted $p = 4.2 \times 10^{-5}$), 291 kynurenine (adjusted $p = 7 \times 10^{-4}$), pyruvic acid (adjusted $p = 1.0 \times 10^{-3}$), 292 kynurenine/tryptophan ratio (adjusted $p = 6.0 \times 10^{-03}$), threonine (adjusted $p = 7 \times 10^{-3}$), 293 294 putrescine (adjusted p = 0.01), ornithine (adjusted p = 0.04), PC as 36:0 (adjusted p = 0.03),

and PC as 40:2 (adjusted p = 0.02) were found in higher concentrations in post-COVID-19 patients relative to the healthy controls.

In addition, lysoPC 14:0 (adjusted p = 0.01), lysoPC 16:0 (adjusted $p = 1.4 \times 10^{-11}$), 297 lysoPC 16:1(adjusted $p = 1.0 \times 10^{-3}$), lysoPC 18:0 (adjusted $p = 3.0 \times 10^{-6}$), LysoPC 17:0 298 (adjusted $p = 1.0 \times 10^{-4}$), LysoPC 20:4 (adjusted $p = 2.0 \times 10^{-3}$), SM(OH)22:1(adjusted p =299 0.04). PC as 32:2 (adjusted p = 0.01), sarcosine (adjusted $p = 1.04 \times 10^{-5}$), taurine (adjusted 300 $p = 4.2 \times 10^{-5}$), and glutamic acid (adjusted $p = 1.0 \times 10^{-3}$) were found downregulated in 301 302 post-COVID-19 patients relative to the healthy controls. Likewise, the glutamine/glutamate ratio (adjusted $p = 2.7 \times 10^{-6}$) was increased in post-COVID-19 patients, while the 303 304 lactate/pyruvate ratio (adjusted p = 0.04) was found to be decreased.

Glucose, kynurenine, C10:2, C18:1, C10:1, lysoPC14:0, lysoPC16:1, PC ae 36:0,
and PC aa 32:2, PC aa 40:2, were found to be in similar concentration levels as for those in
the COVID-19 phase.

Several other metabolites previously related with severity in COVID-19 tend towards normal or healthy levels (kynurenine/tryptophan ratio, C18:2, glutamic acid, glutamine, spermidine) in the post-COVID-19 group. Of note, a group of sphingomyelins (SM(OH)14:0, SM16:0, SM(18:0), SM(OH)16:1, SM(OH)24:1, SM(18:1), SM(16:1)) were found to be normalized, as well as lysoPC 26:0, lysoPC 26:1, lysoPC 28:1, and lysoPC 28:0, phenylalanine, butyric acid, and propionic acid.

The multivariate analysis (PLS-DA) showed a clear separation between both classes (accuracy: 1; R^2 : 0.98; Q^2 :0.89) (Figure 2C). The VIP score plot (Figure 2D) shows that the most important variables that can be used to differentiate negative controls from post-COVID-19 patients are glutamine/glutamate ratio, sarcosine, C18:2, taurine and LysoPC16:0.

A logistic regression model was built using both symptoms and plasma metabolites to distinguish the development of long COVID among COVID-19 patients. The AUC, sensitivity, and specificity values with 95% CI for this model are shown in Supplementary Table 3. A logistic regression model had the following equation: logit(P) = log(P / (1 - P))= 1.13 - 1.724 myalgia - 2.763 ornithine/citrulline + 3.076 lactate/pyruvate, where the numeric value of each named metabolite in the equation is the concentration after autoscaling.

326 Investigating post-COVID-19 patients.

Differences were found in patients from the post-COVID-19 group, both in the frequency of symptoms reported and in the plasma levels of some metabolites such as lactic acid, with a bimodal distribution across the group (**Supplementary Figure 1**). Therefore, these patients were subclassified according to our own scale as a surrogate for disease severity. 18 patients did not report any symptoms (recovered). 17 patients reported less than five persistent symptoms (class A long COVID), while 13 reported more than five symptoms (class B long COVID).

Figure 4 shows the box and whisker plots based on one way ANOVA for class A, class B, and fully recovered patients. The lactate/pyruvate ratio (adjusted p value = 5.8 x 10^{-7}), lactate (adjusted p value = $4.8 \text{ x} 10^{-6}$), arginine ($1.8 \text{ x} 10^{-3}$), ornithine/citrulline ratio (adjusted p value $5. \text{ x} 10^{-3}$), and sarcosine (adjusted p value = 0.02) were the variables best able to differentiate long COVID patients with more than five symptoms from patients with less than five symptoms. Arginine and sarcosine negatively correlated with the number of symptoms.

For differentiating class B long COVID patients from all other post-COVID-19 patients, the lactate/pyruvate ratio had the best performance (AUC: 0.95 (0.92 -0.97),

sensitivity: 0.92 (0.87-0.97), specificity: 0.94 (0.91-0.98)), followed by the combination of
the ornithine/citrulline ratio and uric acid (AUC: 0.92 (0.89-0.95), sensitivity: 0.83 (0.770.90), specificity: 0.84 (0.79-0.90)).

346 Class B patients reported symptoms falling in all the categories, while class A 347 patients reported mainly neuropsychiatric symptoms. We also wanted to know whether the 348 classification based on the group of symptoms would be most appropriate rather than the 349 classification based on the number of symptoms. 18 patients had systemic symptoms, while 350 13 patients reported mostly neuropsychiatric associated disorders. Lactic acid, arginine, the 351 lactate/pyruvate ratio, the ornithine/citrulline ratio and sarcosine were common in both 352 types of long COVID classifications. Long saturated or monounsaturated LysoPCs were 353 found to be increased in patients with neuropsychiatric disorders (Supplementary Figure 354 2).

355 Pathway analysis

Our pathway enrichment analysis (**Figure 5**) shows that the top five metabolic pathways significantly dysregulated (FDR<0.05) in post-COVID patients (relative to controls) were: phospholipids biosynthesis, gluconeogenesis, the glucose-alanine cycle, the Warburg effect, and taurine and hypotaurine metabolism. When comparing class B patients with those recovered, the top five metabolic pathways (FDR<0.05) were: pyruvate metabolism, gluconeogenesis, glycine and serine metabolism, urea cycle metabolism, and the Warburg effect.

363 Plasma IL-17 and leptin

Figure 6 shows plasma concentrations of IL-17 and leptin as measured by ELISA. IL-17
was significantly increased in class B patients relative to class A patients (Mann-Whitney)

test, p = 0.0073) and recovered patients (Mann-Whitney test, p = 0.002). Leptin did not show any statistically significant differences in the three-group comparison.

368

369 **Discussion**

370 Cumulative evidence from the last three years supports the dysregulation of metabolic and 371 immune markers due to SARS-CoV-2 infection [20]. A retrospective cohort study has 372 demonstrated that COVID-19 patients have a significantly higher risk to develop 373 subsequent autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, 374 systemic sclerosis, type I diabetes mellitus, among others [21]. In the present work, our aim 375 was to evaluate the persistence of long-term metabolic alterations in post-COVID-19 376 patients, as well as to measure immune markers that, when chronically produced, can 377 trigger autoimmune diseases.

378 Since well-defined classification or diagnostic criteria are not available for the long 379 COVID assessment, there is an urgent need for molecular methods able to stratify patients 380 according to the severity of the symptoms they are experiencing. Quantitative and validated 381 scales, such as HAM-A, HAM-D, MoCA and mMRC are considered gold standards for 382 neurocognitive impairment and for dyspnea assessment. However, their practical utility 383 could be limited for complex conditions such as long COVID where a broader range of 384 self-reported symptoms with different severity and duration are present. It has been 385 reported that some post-COVID-19 patients complain about extreme cognitive disorders 386 (self-reported symptoms) but without any objective alterations, while others do not report 387 symptoms but exhibit severe cognitive disorders after six to nine months following SARS-388 CoV-2 infection [22]. In our study, several symptoms were corroborated through objective

measures, but with lower rates when using validated scales. Therefore, molecular markersare urgently needed for the correct classification of patients.

391 Our results revealed that 50% of analyzed plasma metabolites showed statistical 392 differences between COVID-19 and post-COVID-19 phases. One of the most dysregulated 393 metabolites was glucose. Montefusco et al. [23] reported glycemic abnormalities in recovered patients two months after the onset of disease. The hyperglycemic state has been 394 395 reported to be even worse in hospitalized patients, pointing to a possible causal role of 396 administered drug regimens, including remdesivir and corticosteroids. These drugs 397 stimulate hepatic gluconeogenesis from amino acids released from muscles, which then 398 inhibits glucose uptake [24].

A number of other metabolites were also found to be dysregulated. Increased plasma pyruvate levels could be both a consequence of glycolytic dysregulation and protein degradation. The increase in putrescine levels in the post-COVID phase may be an indicator of increased protein degradation to help fuel pyruvate metabolism.

403 Taurine and spermidine were found significantly decreased in the post-COVID 404 phase, although a trend towards normalization was observed when compared with controls. 405 Decreased levels of serum taurine have been observed in patients with Myalgic 406 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) [25]. The depleted levels 407 observed in post-COVID-19 phase could explain at least in part the fatigue, since taurine 408 has multiple roles in skeletal muscle, the central nervous system, and energy metabolism. 409 Nevertheless, based on our results, we did not find any correlation between fatigue or 410 myalgia and taurine concentrations in post-COVID-19 patients. Holmes et al. [26] found 411 that taurine levels were increased in post-COVID-19 patients, suggesting hepatic injury, 412 hepatotoxicity, or muscle damage. However, the cohort evaluated in the Holmes study had

a three-month follow-up after the initial infection, which is much shorter than the follow-upused in this study.

Furthermore, we observed increased levels of kynurenine (similar to levels in the COVID-19 acute phase), and a trend towards normalization in tryptophan and the kynurenine/tryptophan ratio in post-COVID-19 patients. This indicates that, although lower in magnitude, the inflammatory conditions attributable to the hyperactivation of this metabolic pathway are still present and may account for some persistent physiological symptoms in these patients.

421 The increase in glutamine (and decrease in glutamate levels) indicates a partial 422 reestablishment of critical processes that took place during the COVID-19 infection phase, 423 such as severe immunometabolic dysregulation. It is well known that SARS-CoV-2 induces 424 metabolic reprogramming in host cells, similar to the Warburg effect in cancer, and a 425 depletion of glutamine has been associated with its consumption for feeding TCA, and as a 426 nitrogen source for nucleotide (ATP) synthesis [27]. On the other hand, glutamate is the 427 most abundant neurotransmitter in the brain. A disruption within the glutamatergic 428 pathway can lead to important neurological consequences, such as cognitive deficits [28]. 429 The glutaminergic dysfunction could be associated with some psychiatric and neurologic 430 symptoms like those reported in the present work.

Alterations in lipid metabolism are evident in most post-COVID-19 patients. These patients exhibited significantly higher levels of carnitine and some short, medium, and long acylcarnitines. These alterations have been largely associated with altered fatty acid metabolism, dysfunctional mitochondria-dependent lipid catabolism, and immune processes or the lysis of white blood cells. Similar results have been reported by Guntur *et al.* [29], pointing to mitochondrial dysfunction, as was also recognized during COVID-19

437 acute phase. Besides, decreased levels of LysoPC 16:0, LysoPC 17:0, LysoPC 18:0, and 438 LysoPC 20:4, were found with respect to negative controls. These reductions have been 439 reported in other inflammatory conditions [30] and other septic processes [31]. Depleted 440 levels of lysophosphatidylcholines and phospholipid ethers, as well as depleted levels of 441 PCs, can impede mitochondrial respiration, as has been also demonstrated in ME/CFS [32]. 442 In line with the lipid dysregulation demonstrated by the targeted metabolomic analysis, 443 routine clinical laboratory tests exhibited elevated levels of total cholesterol, triglycerides, 444 and VLDL, as well as normal levels of HDL and LDL. Xu et al. [33] found increased LDL, 445 triglycerides, total cholesterol, and decreased HDL in survivors of COVID-19, based on a 446 large observational study with participants from the US Department of Veterans Affairs 447 database compared to controls who had never tested positive for COVID-19.

448 As positive findings for the metabolic state of post COVID patients, we found that 449 30 metabolites fell within normal levels. Phenylalanine, which has been widely associated 450 with sepsis and COVID disease severity [20] decreased to normal levels. Beta-451 hydroxybutyric acid and citric acid were also normalized, indicating partial recovery of the 452 tricarboxylic acid cycle [20, 34]. Butyric acid and propionic acid, two short-chain fatty 453 acids that were found to be altered during COVID-19 phase, also fell within normal levels 454 in post-COVID-19 patients, probably indicating that the leaky gut phenomenon and gut 455 dysbiosis detected during COVID infection could be partially reestablished [35]. 456 Spermidine was also normalized. The decrease in spermidine levels could reflect a trend for 457 normalization in overall redox balance. Although excessive levels of spermidine (as those 458 reported in COVID-19 patients) trigger the production of superoxide radicals, optimal 459 concentrations mitigate oxidative stress and diminish overall ROS production [36].

In addition, sphingomyelins and long-chain monounsaturated and saturated LysoPCs were found to be within normal levels. We previously noted altered sphingolipids levels during COVID-19 infection [20]. Sphingolipids play a crucial role in the regulation of signal transduction pathways and in certain pathological conditions, such as inflammation-associated illnesses and innate immune response.

465 In a recent report, Holmes et al. [26] found a high degree of interindividual 466 variability in follow-up patients, reflecting the heterogeneity of post-COVID-19 patients 467 and the fact that long COVID is a spectrum of disorders. Indeed, computationally modeling 468 of the long COVID phenotype data based on electronic healthcare records found six distinct 469 clusters, each with distinct profiles of phenotypic abnormalities [37]. Since symptom 470 classification is still highly subjective, we decided to arbitrarily classify long COVID 471 patients as: class A (less than five symptoms, mainly neuropsychiatric disorders), and class 472 B (more than five symptoms, with a broad spectrum of systemic disorders).

We believe that metabolic information may complement, and partially explain the phenotypic differences among post-COVID-19 patients, and especially in long COVID patients. Xu *et al.* [38] classified recovered patients based on abnormal pulmonary functions, finding increased levels of triacylglycerols, phosphatidylcholines, prostaglandin E2, arginine, and decreased levels of betaine and adenosine in patients with abnormal pulmonary function.

In our work, lactic acid levels were increased in patients with more than five symptoms and systemic disorders (class B patients). Ghali *et al.* [39] found that patients with ME/CFS exhibited elevated blood lactate at rest. Mitochondrial dysfunction, with increased blood lactate, low levels of ATP, and increased levels of oxidative stress markers have been associated to these alterations [40], as well as relative deficiency of mitochondria

type I fibers on muscle biopsies, and low intracellular pH during recovery phase [41–43].
De Boer *et al.* [44] also reported altered lactate levels in long COVID patients, suggesting
that long COVID patients have significant impairment in fat beta-oxidation and
increased blood lactate accumulation even during low-intensity exercise. In contrast,
Guntur *et al.* [29] reported low levels of lactic acid and pyruvate in long COVID patients.
However, this study was conducted in non-hospitalized patients who had recovered from
COVID-19 in March 2020.

Increased level of the lactate/pyruvate ratio in class B patients is another important
indicator of mitochondrial dysfunction. The lactate/pyruvate ratio has been proposed as a
marker for mitochondrial disorders since it indirectly reflects the NADH/NAD+ redox
state[45], lipid metabolism (fat oxidation), and ATP generation. In our study, both markers
(lactate and the lactate/pyruvate ratio) were found positively correlated with fatigue,
myalgia and arthralgias (Spearman correlation, R> 0.6, p< 0.05) (Supplementary Figure
3).

The increased ornithine/citrulline ratio level in class B patients reflects abnormal metabolic activity in the urea cycle. It is notable that Yamano *et al.* [46] reported a similarly increased ornithine/citrulline ratio in CFS patients. An adequate balance of citrulline and ornithine is vital for the clearance of ammonia via urea cycle [47]. If ammonia accumulates intracellularly, the aerobic utilization of pyruvate to feed the TCA cycle is inhibited, resulting in lactate production, which further contributes to fatigue.

In addition, class B patients had decreased levels of arginine. The reduced bioavailability of arginine to produce adequate levels of NO in endothelial cells and vascular tissues leads to the impairment of multiple physiological functions of skeletal muscles, including contractile functions, and muscle repair. This decreased level is not a

residual effect of COVID-19, as the paired study (COVID-19/post-COVID-19) showed normal arginine levels. Arginine is also a substrate for ornithine production by arginase. It is well known that under certain inflammatory conditions, arginase activity is increased [48], producing an excess of ornithine and an imbalance in the urea cycle.

512 Sarcosine was found decreased in class B patients. Previously, Fraser *et al.* [49] 513 found that sarcosine was depressed in COVID-19 patients. Sarcosine plays a vital role in 514 immune functions, as it activates autophagy and the removal of damaged cells. A reduced 515 amount of plasma sarcosine could in part lead to a sustained inflammatory process.

Previous studies have pointed to the persistent immune dysregulation following COVID-19 infection [50]. We found increased levels of monocytes in class B patients. Nuber-Champier *et al.* [51]found that monocyte percentage in the acute phase of the disease allowed them to distinguish between patients with anosognosia for memory deficits in the chronic phase (6–9 months after SARS-CoV-2 infection) and nosognosic patients.

521 We also measured IL-17 levels in post-COVID-19 patients since it is well known 522 that this cytokine is persistently altered in several chronic inflammatory and autoimmune 523 diseases [52], and previous reports have indicated an increased risk of such diseases in COVID-19 patients [21]. IL-17 is a proinflammatory cytokine mainly produced by T helper 524 525 type 17 cells, playing a vital role in the regulation of host immune response against SARS-526 CoV-2. IL-17-induced dysregulated immune responses have been shown to potentially 527 cause hyperinflammatory COVID-19 disease [53]. It has been reported that IL-17 528 downregulates protein phosphatase 6, resulting in increased arginase-1 expression in 529 psoriatic keratinocytes [54]. IL-17A has been found to be associated with neurological 530 sequelae and pulmonary fibrosis in post-COVID-19 patients [55, 56]. Fluctuations in IL-17 531 have been associated with fatigue and fatigue severity in ME/CFS patients [57].

532 Metabolomics is not only useful in providing a snapshot of transient physiological 533 or pathophysiological processes taking place in a living organism, but it has also proven to 534 be a powerful tool for proposing and monitoring therapeutic interventions. In the case of 535 long COVID, a common situation worldwide is that patients have reported an absence of 536 adequate support and a poor recognition of their condition, initially attributed to psychiatric 537 issues. People with long COVID have tried a vast range of self-prescribed medicines, 538 supplements, remedies, and dietary changes to manage the disease and to overcome the 539 effects it has on their quality of life and work capacity. Based on our findings, some 540 interventions could be tested for treating long COVID patients: 1) supplementation of 541 taurine (reducing musculoskeletal disorders); 2) supplementation of arginine and/or 542 citrulline (enhancing ammonia clearance and reducing blood lactate, as well as increasing 543 arginine bioavailability for adequate NO production); 3) supplementation of glutamine 544 (primary source for neurotransmitters and immune function balancing); 4) supplementation 545 of antioxidants such as N-acetylcysteine or NAD+ (redox balance). Similarities found in 546 our results with the ME/CFS pathophysiology may pave the way to common therapeutic 547 interventions for both diseases.

548 We need to acknowledge several limitations with this study. The small sample size 549 was due to the limited number of patients who agreed to participate. While several 550 objective measures of mood and cognition (HAM-A, HAM-D, MoCA mMRC) were used, 551 the sample size did not allow for stratification of patients according to the different test 552 scores obtained, and only self-reported symptoms were used for sub-group classification. 553 Furthermore, we were unable to have a detailed tracking of treatments, medications or 554 alternative therapies during the period evaluated. This limited our interpretation with regard 555 to the impact of pharmacological interventions on the metabolome. Moreover, patients

556 from two different hospitals participated: one private hospital located in Chihuahua city, 557 and one public hospital located in Zacatecas city. In general, private hospital patients have 558 relatively high incomes while public hospital patients have lower incomes. Logistic 559 regression models showed no effects of sex, age, comorbidities, vaccination status or 560 severity during the acute phase in the metabolomic profile associated with long COVID. 561 However, patients from the public hospital reported more systemic symptoms in general, 562 while patients from the private hospital reported principally neuropsychiatric symptoms. A 563 recent study found that patients diagnosed with a post-COVID-19 condition were more 564 likely to be unemployed or on public health insurance, illustrating racial and social 565 disparities in access to and experience with healthcare, at least in the USA [58]. Whether 566 the socioeconomic conditions and lifestyles, along with causes of biological origin 567 influence the metabolic phenoreversion of patients recruited in our study, needs to be 568 further investigated. This is particularly important in countries with significant health 569 system disparities and significant differences in population life conditions.

570

571 Conclusions

To our knowledge, this study is the first describing quantitative metabolic perturbations two years after the initial acute COVID-19 infection using targeted metabolomics. The evolution of post-COVID-19 patients is different, and symptoms are associated to distinctive metabolic patterns resembling, to some extent, the ME/CSF condition. Moreover, the differences observed between the phenotypes of post-COVID-19 patients reveals potential biomarkers that could enable a more accurate and precise molecular classification of long COVID patients beyond classification via self-reported symptoms.

579 List of abbreviations

- 580 COVID-19: Coronoravirus Disease 2019
- 581 LC-MS: Liquid Chromatography-mass spectrometry
- 582 FIA: Flow Injection Analysis
- 583 LysoPCs: Lysophosphatidylcholines
- 584 PACS: Post-Acute COVID-19 Syndrome
- 585 ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- 586 IL-17: Interleukin 17
- 587 PC: Phosphatidylcholine
- 588 SM: Sphingomyelin
- 589 TCA: Tricarboxylic acid
- 590 HAM-A: Hamilton Anxiety Rating Scale
- 591 HAM-D: Hamilton Depression scale
- 592 MoCA: The Montreal Cognitive Assessment
- 593 mMRC: Medical Research Council
- 594

595 Availability of data and materials: The datasets generated and analyzed during the 596 current study are available in the Mendeley repository (<u>https://data.mendeley.com</u>) (doi:

597 10.17632/8zfdjsypd8.1).

598 Ethics approval and consent to participate: The study was revised and approved by the

- 599 Research and Ethics Committees of the Instituto Mexicano de Seguridad Social, with the
- 600 registration number R-2022-3301-038, and Christus Muguerza del Parque Hospital
- 601 (HCMP-CEI-15042020-3, and HCMP-CEI-28022022-A01).
- 602 **Consent for publication**: Not required.

- 603 **Competing interests:** The authors declare that they have no competing interests.
- 604 Funding: CONACyT grant number 311880 "Identificación y validación de marcadores
- 605 inmuno-metábolicos que incrementan la suscpetibilidad a desarrollar formas graves de

606 infección por SARS-CoV-2".

- 607 CONACyT grant number 319503 "Tamizaje masivo de pequeñas moléculas para la
- 608 identificación de biomarcadores y candidatos terapéuticos con alto potencial de efectividad
- 609 contra nuevas variantes de SARS-CoV-2 circulantes a nivel mundial".
- 610 Christus Muguerza del Parque Hospital, Chihuahua, Mexico.
- 611 Instituto Mexicano de Seguridad Social.
- 612 Genome Alberta (a division of Genome Canada) grant number TMIC MC4, the Canadian
- 613 Institutes of Health Research (CIHR) grant number FS 148461, the Canada Foundation for
- 614 Innovation (CFI) grant number MSIF 35456.

615 Authors' contributions

- 616 Study concept and design: YLH and JMA. JCB, DAGL recruited study subjects and
- 617 collected samples. Data acquisition: JZ, JPS, RM and EMM. Statistical analysis: MB, RM.
- 618 Data interpretation: YLH, MB, JMA, JAL, CTC, DSW. Drafting the manuscript: YLH.
- 619 Manuscript editing: CTC. DSW supervised the whole research and revised the original
- manuscript. All the authors contributed to the discussion and gave approval to the finalversion of the manuscript.

622

623 Acknowledgements

JPE-D is a postdoctoral researcher at the Instituto Nacional de Medicina Genómica and
received a fellowship from CONACYT in the program "Estancias Posdoctorales por
México en Apoyo por SARS CoV2 (COVID-19, 2166969)".

630 **References**

- 1. Lam W, Zhong N, Tan W. Overview on SARS in Asia and the World. Respirology.
- 632 2003;8:S2–5.
- 633 2. Al Mutair A, Ambani Z. Narrative review of Middle East respiratory syndrome
- 634 coronavirus (MERS-CoV) infection: updates and implications for practice. Journal of
- 635 International Medical Research. 2020;48:030006051985803.
- 636 3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,
- 637 mechanisms and recommendations. Nat Rev Microbiol. 2023.
- 638 https://doi.org/10.1038/s41579-022-00846-2.
- 639 4. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes
- Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021;174:576–8.
- 5. Wallace PG. Epidemiology: A critical review. Br Med Bull. 1991;47:942–51.
- 642 6. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al.
- 643 Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens:
- 644 prospective cohort study. BMJ. 2006;333:575.
- 645 7. Kukla M, Skonieczna-Żydecka K, Kotfis K, Maciejewska D, Łoniewski I, Lara LuisF, et
- al. COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of
- 647 the Existing Literature. J Clin Med. 2020;9:1420.
- 648 8. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J V. A clinical case definition of post-
- 649 COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–7.
- 650 9. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The
- 651 prevalence and long-term health effects of Long Covid among hospitalised and non-
- hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine.
- 653 2023;55:101762.
- 10. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio
- A, et al. More than 50 long-term effects of COVID-19: a systematic review and metaanalysis. Sci Rep. 2021;11:16144.
- 11. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-
- 658 month respiratory outcomes in patients following COVID-19-related hospitalisation: a 659 prospective study. Lancet Respir Med. 2021;9:747–54.
- 660 12. Schlemmer F, Valentin S, Boyer L, Guillaumot A, Chabot F, Dupin C, et al.
- 661 Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective 662 multicentre study. European Respiratory Journal. 2023;61:2201532.
- 663 13. Pintos-Pascual I, Moreno-Torres V, Ibánez-Estéllez F, Corrales-Rodriguez P, Treviño
- A, Corpas M, et al. Is SARS-CoV-2 the only cause of long-COVID? AIDS Rev. 2022;24.
- 65 14. López-Hernández Y, Monárrez-Espino J, Oostdam A-SH, Delgado JEC, Zhang L,
- 666 Zheng J, et al. Targeted metabolomics identifies high performing diagnostic and prognostic
- 667 biomarkers for COVID-19. Sci Rep. 2021;11:14732.
- 668 15. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, et al. Reliability
- and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-
- 670 A). Depress Anxiety. 2001;13:166–78.
- 671 16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.
- 672 1960;23:56–62.
- 673 17. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et
- al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild
- 675 Cognitive Impairment. J Am Geriatr Soc. 2005;53:695–9.

- 18. Mahler DA, Wells CK. Evaluation of Clinical Methods for Rating Dyspnea. Chest.
- 677 1988;93:580–6.
- 678 19. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for
- 679 metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37 Web
- 680 Server:W652–60.
- 681 20. Herrera-Van Oostdam AS, Castañeda-Delgado JE, Oropeza-Valdez JJ, Borrego JC,
- 682 Monárrez-Espino J, Zheng J, et al. Immunometabolic signatures predict risk of progression
- 683 to sepsis in COVID-19. PLoS One. 2021;16:e0256784.
- 684 21. Chang R, Yen-Ting Chen T, Wang S-I, Hung Y-M, Chen H-Y, Wei C-CJ. Risk of
- autoimmune diseases in patients with COVID-19: a retrospective cohort study.
- 686 EClinicalMedicine. 2023;56:101783.
- 687 22. Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following
- 688 COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain
 689 Behav Immun Health. 2020;9:100163.
- 690 23. Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and
- long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab.
 2021;3:774–85.
- 693 24. Negahdaripour M. Post-COVID-19 Hyperglycemia: A Concern in Selection of
- 694 Therapeutic Regimens. Iran J Med Sci. 2021;46:235–6.
- 695 25. Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic
- 696 encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty
 697 acid and lipid metabolism. Mol Biosyst. 2017;13:371–9.
- 698 26. Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, et al. Incomplete
- 699 Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized
- 700 COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. J
- 701 Proteome Res. 2021;20:3315–29.
- 702 27. Aydın H, Tekin YK, Korkmaz İ, Tekin G, Yurtbay S, Keleş S, et al. Glutamine-Driven
- Metabolic Adaptation to COVID-19 Infection. Indian Journal of Clinical Biochemistry.2023;38:83–93.
- 705 28. Yesilkaya UH, Sen M, Balcioglu YH. COVID-19-related cognitive dysfunction may be
- associated with transient disruption in the DLPFC glutamatergic pathway. Journal ofClinical Neuroscience. 2021;87:153–5.
- 708 29. Guntur VP, Nemkov T, de Boer E, Mohning MP, Baraghoshi D, Cendali FI, et al.
- 709 Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of
- 710 Patients with Post-Acute Sequelae of COVID-19 (PASC). Metabolites. 2022;12:1026.
- 711 30. Engel KM, Schiller J, Galuska CE, Fuchs B. Phospholipases and Reactive Oxygen
- 712 Species Derived Lipid Biomarkers in Healthy and Diseased Humans and Animals A
- 713 Focus on Lysophosphatidylcholine. Front Physiol. 2021;12.
- 714 31. Drobnik W, Liebisch G, Audebert F-X, Fröhlich D, Glück T, Vogel P, et al. Plasma
- 715 ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients.
- 716 J Lipid Res. 2003;44:754–61.
- 717 32. Che X, Brydges CR, Yu Y, Price A, Joshi S, Roy A, et al. Metabolomic Evidence for
- Peroxisomal Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Int J
 Mol Sci. 2022;23:7906.
- 720 33. Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a
- 721 cohort study. Lancet Diabetes Endocrinol. 2023;11:120–8.

- 722 34. Albóniga OE, Jiménez D, Sánchez-Conde M, Vizcarra P, Ron R, Herrera S, et al.
- 723 Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-
- 2 Pathogenesis. J Proteome Res. 2022;21:623–34.
- 725 35. Kim HS. Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-
- 726 19 Severity? mBio. 2021;12.
- 727 36. Firpo MR, Mastrodomenico V, Hawkins GM, Prot M, Levillayer L, Gallagher T, et al.
- 728 Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and
- 729 Entry. ACS Infect Dis. 2021;7:1423–32.
- 730 37. Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al.
- 731 Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER
- 732 programmes. EBioMedicine. 2023;87:104413.
- 733 38. Xu J, Zhou M, Luo P, Yin Z, Wang S, Liao T, et al. Plasma Metabolomic Profiling of
- 734 Patients Recovered From Coronavirus Disease 2019 (COVID-19) With Pulmonary
- 735 Sequelae 3 Months After Discharge. Clinical Infectious Diseases. 2021;73:2228–39.
- 39. Ghali A, Lacout C, Ghali M, Gury A, Beucher A-B, Lozac'h P, et al. Elevated blood
- lactate in resting conditions correlate with post-exertional malaise severity in patients with
 Myalgic encephalomyelitis/Chronic fatigue syndrome. Sci Rep. 2019;9:18817.
- 40. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJF. Oxidative
- stress levels are raised in chronic fatigue syndrome and are associated with clinical
- symptoms. Free Radic Biol Med. 2005;39:584–9.
- 41. Lane RJM, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC. Muscle fibre
- characteristics and lactate responses to exercise in chronic fatigue syndrome. J NeurolNeurosurg Psychiatry. 1998;64:362–7.
- 745 42. Lane RJM, Barrett MC, Taylor DJ, Kemp GJ, Lodi R. Heterogeneity in chronic fatigue
- syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscular
 Disorders, 1008:8:204, 0
- 747 Disorders. 1998;8:204–9.
- 748 43. Petrović V, Buzadz □ić B, Korać A, Vasilijević A, Janković A, Mićunović K, et al.
- 749 Antioxidative defence alterations in skeletal muscle during prolonged acclimation to cold:
- role of <scp>l</scp> -arginine/NO-producing pathway. Journal of Experimental Biology.
 2008;211:114–20.
- 44. de Boer E, Petrache I, Goldstein NM, Olin JT, Keith RC, Modena B, et al. Decreased
- Fatty Acid Oxidation and Altered Lactate Production during Exercise in Patients with Postacute COVID-19 Syndrome. Am J Respir Crit Care Med. 2022;205:126–9.
- 45. Debray F-G, Mitchell GA, Allard P, Robinson BH, Hanley JA, Lambert M. Diagnostic
- Accuracy of Blood Lactate-to-Pyruvate Molar Ratio in the Differential Diagnosis of
 Accuracy of Blood Lactate-to-Pyruvate Molar Ratio in the Differential Diagnosis of
- 757 Congenital Lactic Acidosis. Clin Chem. 2007;53:916–21.
- 46. Yamano E, Sugimoto M, Hirayama A, Kume S, Yamato M, Jin G, et al. Index markers
- of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Sci Rep.
- 760 2016;6:34990.
- 761 47. Walker V. Severe hyperammonaemia in adults not explained by liver disease. Annals of
- 762 Clinical Biochemistry: International Journal of Laboratory Medicine. 2012;49:214–28.
- 763 48. Saligan LN, Lukkahatai N, Jin Zhang Z, Cheung CW, Min Wang X. Altered Cd8+ T
- 764 lymphocyte Response Triggered by Arginase 1: Implication for Fatigue Intensification
- during Localized Radiation Therapy in Prostate Cancer Patients. Neuropsychiatry. 2018;08.
- 766 49. Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, et al.
- 767 Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification
- 768 of Diagnostic and Prognostic Biomarkers. Crit Care Explor. 2020;2:e0272.

- 50. Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. Long-
- term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
 BMC Med. 2022;20:26.
- 51. Nuber-Champier A, Voruz P, Jacot de Alcântara I, Breville G, Allali G, Lalive PH, et
- al. Monocytosis in the acute phase of SARS-CoV-2 infection predicts the presence of
- anosognosia for cognitive deficits in the chronic phase. Brain Behav Immun Health.2022;26:100511.
- 52. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health andDisease. Immunity. 2019;50:892–906.
- 53. Garmendia JV, García AH, De Sanctis CV, Hajdúch M, De Sanctis JB. Autoimmunity
- and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. Curr
 Issues Mol Biol. 2022;45:33–50.
- 54. Lou F, Sun Y, Xu Z, Niu L, Wang Z, Deng S, et al. Excessive Polyamine Generation in
- 782 Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis. Immunity.
- 783 2020;53:204-216.e10.
- 55. Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung Fibrosis
 after COVID-19: Treatment Prospects. Pharmaceuticals. 2021;14:807.
- 56. Saini L, Krishna D, Tiwari S, Goyal JP, Kumar P, Khera D, et al. Post-COVID-19
- 787 Immune-Mediated Neurological Complications in Children: An Ambispective Study.
- 788 Pediatr Neurol. 2022;136:20–7.
- 57. Montoya JG, Holmes TH, Anderson JN, Maecker HT, Rosenberg-Hasson Y, Valencia
- 790 IJ, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome
- patients. Proceedings of the National Academy of Sciences. 2017;114.
- 58. Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding
- ⁷⁹³ long COVID: characterizing a new disease through an ICD-10 lens. BMC Med.
- 794 2023;21:58.
- 795

797 **Figure Legends**

Figure 1: Most common symptoms remaining after 24 months in 48 post-COVID-19
patients. A) Distribution of symptoms according to organ systems. B) Results obtained via
in-person questionnaire.

801

802 Figure 2: Multivariate analysis. A) The volcano plot of the plasma metabolomics between 803 the COVID-19 phase and the post-COVID-19 phase (red represents the up-regulated 804 metabolites compared with COVID-19 phase, green represents the downregulated 805 metabolites compared with COVID-19 phase, and gray represents the metabolites with no 806 difference between both groups. Fold change threshold $\Box = \Box 1.3$ and p-value = 0.05 (FDR 807 adjusted). B) Representative heatmap of top 50 significant metabolites (t-test) in the 808 comparison of COVID-19 and post-COVID-19 phases (red: post-COVID-19 phase; green: 809 COVID-19 phase). C) Score scatter plot based on the two-dimensional PLS-DA (red: post-810 COVID-19 phase; green: COVID-19 phase) D) Rank of the different metabolites (the top 811 15) identified by the PLS-DA according to the VIP score on the x-axis. The most 812 discriminating metabolites are shown in descending order of their coefficient scores. The 813 color boxes indicate whether metabolite concentration is increased (red) or decreased 814 (blue).

815

Figure 3: Multivariate analysis. A) Representative heatmap of top 50 significant metabolites (ANOVA) in the comparison of controls, COVID-19 and post-COVID-19 patients. B) The volcano plot of the plasma metabolomics between controls and post-COVID-19 patients (red represents the up-regulated metabolites compared with controls, green represents the down-regulated metabolites compared with controls, and gray

821	represents the metabolites with no difference between both groups. Fold change
822	threshold $\square = \square 1.3$ and p-value =0.05 (FDR adjusted). C) Score scatter plot based on the
823	two-dimensional PLS-DA (red: controls; green: post-COVID-19 patients) D) Rank of the
824	different metabolites (the top 15) identified by the PLS-DA according to the VIP score on
825	the x-axis. The most discriminating metabolites are shown in descending order of their
826	coefficient scores. The color boxes indicate whether metabolite concentration is increased
827	(red) or decreased (blue).
828	
829	Figure 4: Box plots for some significantly altered metabolites ($p < 0.05$) in plasma of class
830	A patients (less than five symptoms), class B patients (more than five symptoms), and
831	recovered patients. The bar plots show the original and normalized values (mean +/- one
832	standard deviation). Medians are indicated by horizontal lines within each box.
833	
834	Figure 5: Metabolic pathway analysis. Predicted metabolic pathways with p-
835	value $\Box \leq \Box 0.05$ are listed. A) controls vs. post-COVID-19 patients. B) class B patients vs.
836	recovered patients.
837	
838	Figure 6: Concentrations of IL-17 and leptin measured by ELISA in post-COVID-19

- patients. Graphs were constructed in GraphPad Prism v8.0. The ** p value <0.01 was
- 840 calculated using Kruskall-Wallis tests with Dunn's post-tests.



Neurologic
 Psychiatric
 Respiratory
 Cardiologic
 Digestive
 Cutaneous
 Systemic



Percentage

В









В







Ornithine/Citrulline







A) Controls vs. post-COVID patients

B) Class B patients vs. recovered patients

Enrichment Overview (top 25)





